# US 10,500,275 B2 · Superovulation in mice comprising administration of anti-inhibin serum and equine chorionic gonadotropin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,275 B2
- Document ID: US10500275B2
- Status: Granted
- Kind: B2
- Application number: 15/552,257
- Filed: 2016-02-19
- Published: 2018-04-19
- Granted: 2019-12-10
- Earliest claimed: 2015-02-20
- Assignees: National University Corporation Kumamoto University
- Applicants: National University Corporation Kumamoto University
- Inventors: Naomi Nakagata; Toru Takeo
- Web page: https://patentgrep.com/patent/US10500275B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A01K 67/02: Breeding vertebrates
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 5/24: of the sex hormones
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 2227/105: Murine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide a novel method that is excellent in superovulation induction efficiency. Specifically, it is an object to provide a method giving superior superovulation induction efficiency as compared with conventional methods using equine chorionic gonadotropin (eCG) and human chorionic gonadotropin (hCG). The present invention provides a superovulation inducing method, comprising simultaneously administering anti-inhibin antibody and equine chorionic gonadotropin (eCG), then, administering human chorionic gonadotropin (hCG), to a female mouse.

## Claims

### Claim 1

A superovulation inducing method, comprising simultaneously administering to a female mouse (a) anti-inhibin antibody and equine chorionic gonadotropin (eCG), (b) followed by human chorionic gonadotropin (hCG).

### Claim 2 (depends on 1)

The superovulation inducing method according to claim 1, wherein the anti-inhibin antibody is administered in the form of inhibin antiserum.

### Claim 3 (depends on 2)

The superovulation inducing method according to claim 2, wherein the female mouse is a 3 to 30-week old female mouse.

### Claim 4 (depends on 3)

The superovulation inducing method according to claim 3, wherein the female mouse is 3 to 5 weeks of age.

### Claim 5 (depends on 4)

The superovulation inducing method according to claim 4, wherein the female mouse is a C57BL/6 strain female mouse.

### Claim 6 (depends on 5)

The superovulation inducing method according to claim 5, wherein the dosage of the inhibin antiserum is 0.4 mL or less.

### Claim 7 (depends on 6)

The superovulation inducing method according to claim 6, wherein the dosage of the inhibin antiserum is between 0.05 mL and 0.4 mL.

### Claim 8 (depends on 7)

The superovulation inducing method according to claim 7, wherein the dosage of the equine chorionic gonadotropin is between 1 IU and 10 IU.

### Claim 9 (depends on 2)

The superovulation inducing method according to claim 2, wherein the dosage of the inhibin antiserum is between 0.05 mL and 0.4 mL.

### Claim 10 (depends on 1)

The superovulation inducing method according to claim 1, wherein the female mouse is a 3 to 30-week old female mouse.

### Claim 11 (depends on 1)

The superovulation inducing method according to claim 1, wherein the female mouse is a C57BL/6 strain female mouse.

### Claim 12 (depends on 1)

The superovulation inducing method according to claim 1, wherein the dosage of the equine chorionic gonadotropin is between 1 IU and 10 IU.

### Claim 13 (depends on 1)

An in vitro fertilization method comprising
(i) a step of producing an oocyte and/or ovum using the method according to claim 1, and
(ii) a step of fertilizing the oocyte and/or ovum produced by step (i) with sperm from a genetically engineered mouse.

### Claim 14 (depends on 13)

The in vitro fertilization method according to claim 13, wherein the sperm is derived from a C57BL/6 strain male mouse.